Rare diseases
Investigational molecules
Locations
2656 State Street, 92008-1626, United States
Tyra Biosciences Inc. focuses on clinical research in advanced urothelial carcinoma and non-muscle invasive bladder cancer (NMIBC), with an emphasis on tumors linked to FGFR3 alterations. Its studies address disease settings where targeted treatment strategies are being explored in genitourinary oncology.
The sponsor’s clinical programme includes both localized bladder cancer and more advanced urinary tract malignancies, reflecting interest in disease control across distinct stages of urothelial disease.
Tyra Biosciences Inc. runs clinical trials in conditions such as Transitional cell carcinoma, Bladder transitional cell carcinoma, Neoplasm malignant, Neoplasm, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Bulgaria
FranceFranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
